IMS关于中国创新药物研发的报告.pdf

Sowing the Seeds of a Blockbuster Launch in China SECOND IN A THREE- ART SERIES By J an Willem Eleveld and Mandy Chui I Chi a, however p romisi g a ew drug p roduct is, • Poor local healthcare coverage, once a maj or deterrent to bei g f irst-to-market is o g uara tee of its success. The growth, is now being remedied by a national government that is committed to extending universal medical health- lau ch of a y ew drug should be studied a d p la ed care to cover more than 90% of the population by the way i adva ce — a d creati g the categ ory a d the year 2011. market must be built f rom the g rou d up. • nvestment in the country’s vast network of community hospitals is up, while the government works to reduce t is the new reality — at a time when once-prosperous pressure on overcrowded city hospitals. markets around the world have become nothing less than • Patient needs and perceptions are changing — as the anemic, China remains one of the few countries where public’s demand for better healthcare grows stronger, so global companies stand to keep growing. With GDP steadily rising faster than other emerging nations such as Brazil, ndia and Russia, China is proj ected FIG 1: to become the world’s largest economy j ust 10 years from NEW CHEMICAL ENTITY LAUNCHES — SELECT now. This bodes extremely well for healthcare companies COUNTRIES (1997-2008) ready to take the plunge. Last year alone, China’s pharma-